CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

Arlocabtagene autoleucel：一种用于重度预治疗复发/难治性多发性骨髓瘤的靶向 GPRC5D CAR-T 细胞疗法

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

抗 BCMA/GPRC5D CAR-T 细胞用于伴骨外髓外病变的复发/难治性多发性骨髓瘤患者

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

我如何治疗浆细胞白血病

How I treat plasma cell leukemia.

BCMA 靶向治疗后的复发/难治性多发性骨髓瘤的后续 CAR-T 与工程化抗体：系统综述与荟萃分析

Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-anal

BCMA 与 GPRC5D 嵌合抗原受体（CAR）T 细胞同时输注治疗晚期多发性骨髓瘤

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

接受 BiTEs 和 CAR-T 细胞治疗的多发性骨髓瘤感染风险的真实世界证据：一项荟萃分析

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

在真实世界实践中，接受 T 细胞重定向治疗的 RRMM 患者中约每 4 例就有 1 例发生严重感染。

将下一代免疫治疗纳入多发性骨髓瘤治疗

Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma.

Arlocabtagene Autoleucel（GPRC5D CAR-T）治疗多发性骨髓瘤：II 期临床试验

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

这是一项 II 期注册临床试验，评估细胞治疗用于多发性骨髓瘤的疗效与安全性。研究设计：2 个分组。当前状态：招募中。计划入组 230 例。试验地点：美国 · 伯明翰、吉尔伯特、小石城、洛杉矶（共 52 个中心）。登记号：NCT06297226。

多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸

Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.